UCSF Benioff Children's Hospital Antimicrobial Susceptibility Gram-negatives Inpatient/ED 2014-2016

PrintPrintPDFPDF

N/A-testing NOT APPLICABLE to organism. CZOL-cefazolin, CTRX-ceftriaxone, CTAZ-ceftazidime, CFPM-cefepime, GEN-gentamicin, TOB-tobramycin, T/S-trimethoprim/sulfamethoxazole, CIP-ciprofloxacin, MER-meropenem, P/T-piperacillin-tazobactam

Values are % of strains testing susceptible to listed antibiotic. Unless indicated, results are for all inpatient/ED locations and culture sites.

Susceptibilities are based on combined data from 2014-2016. Isolate numbers and 95% confidence intervals are provided to gauge precision of susceptibility estimate. 

Organism Total Isolates

CZOL

%S

(95% CI)

CTRX

%S

(95% CI)

CTAZ

%S

(95% CI)

CFPM

%S

(95% CI)

GEN

%S

(95% CI)

TOB

%S

(95% CI)

T/S

%S

(95% CI)

CIP

%S

(95% CI)

P/T

%S

(95% CI)

MER

%S

(95% CI)

Acinetobacter baumanii

6*  N/A

17

(0,64)

 100

(54,100)

 83

(36,100)

100

(54,100)

100

(54,100)

 100

(54,100)

 100

(54,100)

83

(36,100)

100

(54,100)

Citrobacter freundii

16*

N/A

75

(48,93)

88

(62,98)

100

(79,100)

94

(70,100)

94

(70,100)

88

(62,98)

94

(70,100)

94

(70,100)

100

(79,100)

Enterobacter aerogenes

19*

N/A

N/A

N/A

100

(83,100)

100

(83,100)

100

(83,100)

100

(83,100)

100

(83,100)

80

(56,94)

100

(83,100)

Enterobacter cloacae

62

N/A

N/A

N/A

98

(91,100)

98

(91,100)

98

(91,100)

94

(84,98)

100

(94,100)

89

(78,95)

100

(94,100)

Escherichia coli

433

70**

(66,74)

90

(86,92)

92

(89,95)

96

(93,97)

91

(88,94)

92

(89,95)

69

(64,73)

90

(87,93)

99

(98,100)

100

(99,100)

Klebsiella oxytoca

38

13**

(4,28)

92

(79,98)

97

(86,100)

97

(86,100)

97

(86,100)

97

(86,100)

89

(75,97)

97

(86,100)

92

(79,98)

100

(91,100)

Klebsiella pneumoniae

102

77**

(68,85)

94

(88,98)

96

(90,99)

98

(93,100)

93

(86,97)

96

(90,99)

82

(74,89)

95

(89,98)

97

(92,99)

100

(96,100)

Proteus mirabilis

47

17**

(8,31)

100

(92,100)

100

(92,100)

100

(92,100)

94

(82,99)

94

(82,99)

89

(77,96)

100

(92,100)

100

(92,100)

100

(92,100)

Pseudomonas aeruginosa

103***

N/A

N/A

90

(83,95)

91

(84,96)

N/A

98

(93,100)

N/A

90

(83,95)

88

(81,94)

89

(82,95)

ICU

40

N/A

N/A

85

(70,94)

88

(73,96)

N/A

98

(87,100)

N/A

80

(64,91)

83

(67,93)

83

(67,93)

non-ICU

63

N/A

N/A

94

(84,98)

94

(84,98)

N/A

98

(91,100)

N/A

97

(89,100)

92

(82,97)

94

(85,98)

Serratia marcescens

26*

N/A

96

(80,100)

100

(86,100)

100

(87,100)

96

(80,100)

96

(80,100)

96

(80,100)

100

(87,100)

92

(75,99)

100

(87,100)

*When fewer than 30 isolates are reported, % susceptible may not reflect robust estimate of population susceptibility

**Reporting of Cefazolin susceptibility for E. coli, Klebsiella spp and Proteus is based on breakpoints for complicated infections - see outpatient E. coli susceptibilities for reporting based on uncomplicated UTI breakpoints

***Pseudomonas aeruginosa isolates do not include isolates from cystic fibrosis patients